gvtcx

Purchase of purified hyperimmune Equine Tetanus Antitoxin

MHRA Buyer Organisation Published 28 Feb 2019 Contracts Finder

key details

Statusplanning
Category (CPV) 03140000 +12 more
RegionEast of England
SME suitableNo
OCIDocds-b5fd17-09919021-1608-4399-b8fa-ef1fd4854a74

description

The Agency requires the purchase of purified hyperimmune Equine Tetanus Antitoxin for use in the development of a replacement biological reference material.

An overview of the requirement is: hyperimmune equine tetanus antitoxin obtained from the repeated immunisation of horses with tetanus toxoid and toxin. The suitable material would have a potency of at least 1,500 IU/ml in a total volume of not less than 5 L and will be purified F(ab)2. Material to be supplied in 2019.

As far as we are aware there is only one supplier who is able to meet this very specific request. Potential suppliers if they feel they can meet the requirement should email Nawaz.habib@nibsc.org to register an interest.

If no submissions of potential interest are received by close of play 14 March 2019, it is then intended to perform a direct award without competition to the sole supplier we believe can deliver the required service.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
28 Feb 2019 Planning (planning) · 4d7f9c83-cb59-4bd7-bccc-b83673450bd3-272844
1 May 2019 Tender (tender) · 4afa90e3-0eec-4eed-bf92-f637aaadd1f7-286967

more from MHRA Buyer Organisation

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.